OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HEMT51

Hemant Surgical Industries Ltd

Medical Equipment, Supplies & DistributionVerified

Hemant Surgical Industries Ltd has a basic and diluted share count of 13,038,400 shares outstanding, indicating no dilution from potential share issuance at this time. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's profitability and returns metrics are not available in the current dataset, which limits the ability to compare its performance against industry_config preferred metrics or cohort medians. Without these metrics, it is not possible to determine whether the company is outperforming or underperforming its peers in terms of profitability. Segment and geographic exposure data are not disclosed in the available source documents, making it difficult to assess revenue concentration or geographic diversification. This lack of information hinders the ability to evaluate the company's exposure to regional economic conditions or market-specific risks. Growth trajectory data is also not available in the current dataset, preventing an assessment of the company's revenue history or future outlook. Without numeric deltas or forward-looking guidance, it is not possible to determine whether the company is experiencing growth or contraction in its core operations. The risk assessment indicates a low level of dilution risk, but liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. This suggests that while the company is not currently facing significant dilution pressure, its liquidity position remains unclear. Recent events, including filings and transcripts, are not disclosed in the available source documents, which limits the ability to assess the company's recent performance or strategic direction. Without this information, it is not possible to determine whether the company has experienced any material changes in its operations or financial condition.

30-day price · HEMT+105.80 (+41.3%)
Low$215.00High$361.80Close$361.80As of11 May, 00:00 UTC
Profile
CompanyHemant Surgical Industries Ltd
TickerHEMT.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Hemant Surgical Industries Ltd has a basic and diluted share count of 13,038,400 shares outstanding, indicating no dilution from potential share issuance at this time. However, the liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. The company's profitability and returns metrics are not available in the current dataset, which limits the ability to compare its performance against industry_config preferred metrics or cohort medians. Without these metrics, it is not possible to determine whether the company is outperforming or underperforming its peers in terms of profitability. Segment and geographic exposure data are not disclosed in the available source documents, making it difficult to assess revenue concentration or geographic diversification. This lack of information hinders the ability to evaluate the company's exposure to regional economic conditions or market-specific risks. Growth trajectory data is also not available in the current dataset, preventing an assessment of the company's revenue history or future outlook. Without numeric deltas or forward-looking guidance, it is not possible to determine whether the company is experiencing growth or contraction in its core operations. The risk assessment indicates a low level of dilution risk, but liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents. This suggests that while the company is not currently facing significant dilution pressure, its liquidity position remains unclear. Recent events, including filings and transcripts, are not disclosed in the available source documents, which limits the ability to assess the company's recent performance or strategic direction. Without this information, it is not possible to determine whether the company has experienced any material changes in its operations or financial condition.
Key takeaways
  • Hemant Surgical Industries Ltd has no dilution from potential share issuance at this time.
  • The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
  • Profitability and returns metrics are not available, limiting the ability to compare the company's performance against industry benchmarks.
  • Segment and geographic exposure data are not disclosed, making it difficult to assess revenue concentration or geographic diversification.
  • Growth trajectory data is not available, preventing an assessment of the company's revenue history or future outlook.
  • --
  • **RATIONALES**:
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$597.6M$24.4M$11.5M-$6.1M
FY-3$1.04B$46.5M$27.2M$36.3M
FY-2$1.09B$96.2M$76.4M$45.6M
FY-1$1.06B$97.9M$98.0M$53.0M
FY0$1.07B$82.8M$80.4M-$281.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$429.0M$96.1M$15.2M
FY-3$533.1M$118.6M$58.3M
FY-2$646.9M$233.6M$84.6M
FY-1$966.4M$548.6M
FY0$1.48B$631.7M
PeriodOCFCapExFCFSBC
FY-4-$2.7M-$23.9M-$6.1M
FY-3$154.7M-$4.2M$36.3M
FY-2$60.0M-$39.3M$45.6M
FY-1-$75.6M-$55.2M$53.0M
FY0$88.4M-$375.7M-$281.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricHEMTActivity
Op margin3.9% medp25 -31.3% · p75 14.4%
Net margin2.4% medp25 -30.5% · p75 11.1%
Gross margin46.7% medp25 28.2% · p75 63.1%
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-4.8% medp25 -11.6% · p75 -2.4%
Debt / equity17.9% medp25 2.7% · p75 52.2%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-11 01:18 UTC#4ba341f1
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 02:54 UTCJob: e4410500